Recursion Pharmaceuticals (RXRX) Share-based Compensation (2020 - 2026)

Recursion Pharmaceuticals' Share-based Compensation history runs 6 years deep, the most recent figure standing at $22.2 million for Q1 2026.

• Quarterly Share-based Compensation fell 38.39% year-over-year to $22.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.4 million (down 85.02% YoY) and the FY2025 annual result came in at $111.2 million, down 82.35% from the prior year.
• Share-based Compensation was $22.2 million for Q1 2026 at Recursion Pharmaceuticals, down from $90.9 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $630.1 million in Q4 2024 and bottomed at -$41.9 million in Q3 2025.
• A 5-year average of $48.1 million and a median of $16.1 million in 2023 frame the typical range for Share-based Compensation.
• Peak annual rise in Share-based Compensation reached 3817.22% in 2024, while the deepest fall reached 294.44% in 2024.
• Recursion Pharmaceuticals' Share-based Compensation stood at -$4.0 million in 2022, then surged by 507.24% to $16.1 million in 2023, then surged by 3817.22% to $630.1 million in 2024, then slumped by 85.57% to $90.9 million in 2025, then slumped by 75.56% to $22.2 million in 2026.
• Business Quant data shows RXRX's Share-based Compensation at $22.2 million in Q1 2026, $90.9 million in Q4 2025, and -$41.9 million in Q3 2025.